Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Ometac


DESCRIPTION

OMETAC 10: Opaque pink coloured hard gelatine capsule.
OMETAC 20: Opaque pink / reddish brown hard gelatin capsule with OMETAC 20 printed on body and cap.


COMPOSITION

OMETAC 10: Each capsule contains Omeprazole (as enteric-coated pellets) 10 mg

OMETAC 20: Each capsule contains Omeprazole (as enteric-coated pellets) 20 mg

ACTION & PHARMACOLOGY

Omeprazole inhibits secretion of gastric acid and is considered to do so by irreversibly blocking the enzyme system of hydrogen / potassium adenosine triphosphatase, the so-called proton pump of the gastric parietal cell. It thereby inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen. Omeprazole inhibits both basal and stimulated acid secretion irrespective of the stimulus. Omeprazole also inhibits hepatic cytochrome P-450 mixed-function oxidase system. Omeprazole is acid-labile and absorption from the gastrointestinal tract appears to be formulation-dependent and dose dependent. Following absorption, it is distributed in tissues, particularly gastric parietal cells. Approximately 95% of the drug is bound to plasma proteins. Omeprazole is almost completely metabolised in the liver and rapidly eliminated mostly in the urine (about 80%) and faeces (about 20%). Although the elimination half life from plasma is short (0.5 to 1.5 hour), it's duration of action can last up to 72 hours. The inhibition of acid secretion is directly related to the area under the plasma concentration time curve but not to the plasma concentration at any given time.


INDICATIONS

Treatment of duodenal and benign gastric ulcers including those complicating NSAID therapy. Treatment of reflux oesophagitis, Zollinger-Ellison syndrome. Prophylactic treatment in patients with an increased risk of NSAID-associated gastric ulcers, duodenal ulcers, gastroduodenal erosions or dyspeptic symptoms.


CONTRAINDICATIONS

Contraindicated in patients sensitive to the drug.


SIDE EFFECTS

Omeprazole is generally well-tolerated and adverse reactions are mostly mild and reversible. Adverse effects which have been reported and which may occur rarely in isolated cases include haematological disorders (anaemia, eosinopenia, leukocytosis, neutropenia, thrombocytopenia, haematuria), gastrointestinal disturbances (diarrhoea, constipation, nausea, vomiting, flatulence, abdominal pain, heartburn), endocrinological disturbances (gynaecomastia), hepatic abnormalities (hepatitis with or without jaundice, hepatic failure, elevated liver enzymes), dermatological disorders (skin rashes, pruritus, photosensitivity, erythema multiforme), urinary tract infection, dizziness, headache, muscle pain, malaise, fever.


PRECAUTIONS

When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with omeprazole is instituted, as treatment may alleviate symptoms and delay diagnosis. Caution should be exercised in patients with chronic hepatic disease or a history of liver disease as this condition may cause the drug to accumulate in the body.


Use in pregnancy and lactation: Studies have not been done in humans. However studies in animals have shown that omeprazole may cause harm to the fetus. Use of the drug should be avoided in pregnancy unless there is no safer alternative. There is no information available on the passage of omeprazole into milk or its effects on the neonate. Breastfeeding should therefore be discontinued if the use of omeprazole is considered essential.

 

Use in children: There is no previous experience of the use of omeprazole in children.


Drug interaction: Concurrent use of omeprazole with diazepam, anticoagulants and phenytoin may increase the blood levels of the latter drugs, thereby increasing the propensity for side-effects.


Omeprazole may increase gastrointestinal pH, and concurrent administration of omeprazole with ketoconazole may reduce absorption of the latter. Concomitant administration of omeprazole with digoxin may result in increased bioavailability of digoxin because of the increased gastrointestinal pH.

 

DOSAGE & ADMINISTRATION

Ometac Capsules are recommended to be taken in the morning and swallowed whole with liquid. For patients with swallowing difficulties, the capsules may be opened and the contents swallowed or suspended in a slightly acidic fluid such as juice, soured milk or non-carbonated water. The dispersion should be taken immediately or within 30 minutes. Alternatively, patients can suck the capsule and swallow the pellets with liquid. The pellets must not be chewed or crushed.


For duodenal benign gastric ulcers: The usual dose is 20 mg once daily. Symptom resolution is rapid. The majority of patients with duodenal ulcer are healed after 4 weeks, while patients with benign gastric ulcers are healed after 8 weeks. In severe cases, the dose may be increased to 40 mg once daily, and healing is usually achieved within 4 weeks.


Long-term therapy for patients with a history of recurrent duodenal ulcer is recommended at a dose of 20 mg once daily, up to one year.
For prevention of relapse in patients with duodenal ulcer disease, the recommended dose is 10 mg daily. If necessary, dosage may be increased to 20 mg - 40 mg once daily.


The effectiveness of Ometac is not affected by simultaneous NSAID treatment, and the usual dose and duration of treatment is recommended.

 

For reflux oesophagitis: The recommended dosage is 20 mg once daily.


Symptoms resolve rapidly and most patients are healed within 4 weeks. For those who are not fully healed after the initial course, healing usually occurs during a further 4 weeks' treatment period.


In patients with severe reflux oesophagitis, 40 mg once daily is recommended and healing is usually achieved within 8 weeks.


For long-term management of patients with healed reflux oesophagitis, the recommended dose is 10 mg once daily. If required, dosage may be increased to 20-40 mg once daily.


For Zollinger-Ellison syndrome: The recommended initial dosage is 60 mg once daily. The dosage should be adjusted individually and treatment continued as long as is clinically indicated. All patients with severe disease and inadequate response to other therapies have been effectively controlled and more than 90% of patients maintained on doses of 20 - 120 mg daily. With doses above 80 mg daily, the dose should be divided and given twice daily.


For the prophylaxis of NSAID-associated gastric ulcers, duodenal ulcers, gastroduodenal erosions and dyspeptic symptoms: The recommended dosage is 20 mg once daily.


Use in children: There is no previous experience of the use of omeprazole in children.


Use in elderly: Generally, dosage adjustment is not necessary in the elderly.


Use in patients with impaired renal or hepatic function:

Impaired renal function: Dosage adjustment is not required in impaired renal function.

Impaired hepatic function: As bioavailability and plasma half-life of omeprazole are increased in patients with impaired hepatic function, a daily dose of 10 - 20 mg daily may be sufficient.


OVERDOSAGE & TREATMENT

Symptoms include blurred vision, confusion, diaphoresis, drowsiness, dryness of mouth, flushing, headache, nausea, tachycardia. Since there is no specific antidote, treatment should be symptomatic and supportive.


PRESENTATION

OMETAC 10: 28's
OMETAC 20: 14's


STORAGE:

Store in a dry place below 25C.
Keep medicines out of reach of children. Shelf Life: Please refer outer carton for shelf life.

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer